HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kaushik P Patel Selected Research

Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)

1/2020Central angiotensin II-Protein inhibitor of neuronal nitric oxide synthase (PIN) axis contribute to neurogenic hypertension.
1/2019Exercise training augments neuronal nitric oxide synthase dimerization in the paraventricular nucleus of rats with chronic heart failure.
1/2018Specific Afferent Renal Denervation Prevents Reduction in Neuronal Nitric Oxide Synthase Within the Paraventricular Nucleus in Rats With Chronic Heart Failure.
1/2016Renal Denervation Improves Exaggerated Sympathoexcitation in Rats With Heart Failure: A Role for Neuronal Nitric Oxide Synthase in the Paraventricular Nucleus.
11/2011Gene transfer of neuronal nitric oxide synthase to the paraventricular nucleus reduces the enhanced glutamatergic tone in rats with chronic heart failure.
8/2005Gene transfer of neuronal nitric oxide synthase to carotid body reverses enhanced chemoreceptor function in heart failure rabbits.
10/2003nNOS gene transfer to RVLM improves baroreflex function in rats with chronic heart failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kaushik P Patel Research Topics

Disease

46Heart Failure
01/2022 - 04/2002
12Hypertension (High Blood Pressure)
01/2022 - 11/2002
7Type 1 Diabetes Mellitus (Autoimmune Diabetes)
09/2013 - 10/2006
6Diabetes Mellitus
01/2017 - 08/2001
4Myocardial Infarction
12/2020 - 06/2005
4Cardiovascular Diseases (Cardiovascular Disease)
01/2020 - 03/2007
3Ischemia
11/2021 - 12/2020
3Hypoxia (Hypoxemia)
11/2016 - 08/2005
3Erectile Dysfunction
09/2013 - 03/2007
3Infarction (Infarctions)
05/2013 - 10/2011
2Hemorrhage
11/2021 - 11/2021
2Cardiomyopathies (Cardiomyopathy)
01/2021 - 02/2004
2Tachycardia (Tachyarrhythmias)
10/2020 - 01/2005
2Type 2 Diabetes Mellitus (MODY)
01/2019 - 01/2014
2Infections
10/2012 - 04/2012
1Hyperalgesia
11/2021
1Hypesthesia (Numbness)
11/2021
1Chronic Renal Insufficiency
11/2021
1Obesity
11/2021
1Wounds and Injuries (Trauma)
11/2021
1Necrosis
11/2021
1Edema (Dropsy)
11/2021
1Inflammation (Inflammations)
09/2021
1Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder)
09/2021
1Neoplasms (Cancer)
01/2020
1Chronic Kidney Failure (Chronic Renal Failure)
01/2017
1Bradycardia
04/2016
1Diabetic Cardiomyopathies
01/2016
1AIDS-Related Complex (ARC)
07/2013
1Chronic Disease (Chronic Diseases)
10/2012

Drug/Important Bio-Agent (IBA)

16Nitric Oxide (Nitrogen Monoxide)FDA Link
01/2022 - 08/2001
9Angiotensin IIIBA
01/2021 - 02/2004
7Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA
01/2020 - 10/2003
7Nitric Oxide Synthase (NO Synthase)IBA
06/2012 - 08/2001
6Streptozocin (Streptozotocin)FDA Link
11/2011 - 08/2001
5Superoxides (Superoxide)IBA
09/2021 - 08/2001
5Proteins (Proteins, Gene)FDA Link
01/2020 - 08/2001
5AngiotensinsIBA
10/2013 - 07/2004
5salicylhydroxamic acid (SHAM)IBA
06/2012 - 01/2005
3SodiumIBA
01/2022 - 03/2011
3Messenger RNA (mRNA)IBA
11/2016 - 10/2004
3Glutamic Acid (Glutamate)FDA Link
11/2016 - 06/2008
3N-Methylaspartate (NMDA)IBA
05/2010 - 11/2003
2CytokinesIBA
11/2021 - 07/2008
2Glucagon-Like Peptide 1 (GLP 1)IBA
11/2021 - 01/2020
2Norepinephrine (Noradrenaline)FDA LinkGeneric
09/2021 - 01/2021
2MicroRNAs (MicroRNA)IBA
01/2021 - 10/2016
2CatecholaminesIBA
01/2019 - 01/2016
2NADPH Oxidases (NAD(P)H oxidase)IBA
01/2016 - 10/2006
2EnzymesIBA
01/2016 - 12/2011
1Sodium-Glucose Transport ProteinsIBA
12/2021
1Pharmaceutical PreparationsIBA
11/2021
1masitinibIBA
11/2021
1Therapeutic UsesIBA
11/2021
1EndopeptidasesIBA
11/2021
1sacubitrilIBA
11/2021
1Hormones (Hormone)IBA
11/2021
1Neprilysin (Neutral Endopeptidase)IBA
11/2021
1AMP-Activated Protein KinasesIBA
12/2020
1Metalloproteases (Metalloproteinases)IBA
12/2020
1Beclin-1IBA
12/2020
1Sirolimus (Rapamycin)FDA Link
12/2020
1Connexin 43 (Connexin43)IBA
12/2020
17-Ala-angiotensin (1-7)IBA
10/2020
1PorphyrinsIBA
01/2020
1Superoxide DismutaseIBA
01/2020
1ManganeseIBA
01/2020
1Aquaporin 2IBA
11/2019
1Epithelial Sodium ChannelsIBA
11/2019
1Glucagon-Like Peptide-1 ReceptorIBA
01/2019
1LiraglutideFDA Link
01/2019
1AngiotensinogenIBA
05/2017
1Autonomic AgentsIBA
01/2017
1ChromatinIBA
11/2016
1N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
11/2016
1methylatropineIBA
04/2016
14- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA
01/2016
1NAD (NADH)IBA
01/2016
1Adrenergic Receptors (Adrenergic Receptor)IBA
01/2016
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2016
1Glutamate Receptors (Glutamate Receptor)IBA
03/2015
1Dopamine (Intropin)FDA LinkGeneric
01/2014
1Peptides (Polypeptides)IBA
10/2013
1GABA Receptors (GABA Receptor)IBA
07/2013
1BicucullineIBA
07/2013
1Adrenergic Agents (Adrenergic Drugs)IBA
05/2013
1dimethylarginineIBA
06/2012
1Neurotransmitter Agents (Neurotransmitter)IBA
06/2012
1arginine methyl esterIBA
06/2012
1symmetric dimethylarginineIBA
06/2012
1CalciumIBA
04/2012
1Angiotensin-Converting Enzyme 2IBA
12/2011
1AldosteroneIBA
10/2011
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
10/2011
1Ouabain (G Strophanthin)IBA
10/2011
1Type 1 Angiotensin ReceptorIBA
10/2011

Therapy/Procedure

9Denervation
11/2021 - 05/2015
6Ligation
11/2021 - 11/2003
3Therapeutics
01/2019 - 10/2012
2Tourniquets
11/2021 - 11/2021